Elotuzumab spares dendritic cell integrity and functionality

Schlaweck, Sebastian; Strauss, Leon; Daecke, Solveig Nora; Brossart, Peter; Heine, Annkristin

doi:10.1007/s00432-021-03572-z

Cited by 1 publication

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, SLAMF7+ CD8+ Treg cells could be eliminated via ADCC, contributing to reduce immunosuppression [142]. Finally, elotuzumab seems not only to spare the function of DCs, but also to enhance the IL-2 immune response of DCs induced by IMiDs [143,144].…”

Section: Influence Of Anti-mm Drugs On the Mementioning

confidence: 99%

“…Denosumab Anti-RANKL [93] -Inhibition of OC activity [94,95] Daratumumab Anti-CD38 ADCC ADCP CDC [123] -Inhibition of CD38+ Tregs [124] -Inhibition of CD38+ Bregs [124] -Inhibition of CD38+ MDSCs [124] -Reduction of CD38+ NK cells [124,126,127] -Increase in CD8+ T-cell cytotoxicity [124] -Inhibition of osteoclastogenesis [131,132] Isatuximab Anti-CD38 ADCC ADCP CDC [124] -Inhibition of CD38+ Tregs [128] -Inhibition of CD38+ Bregs [128] -Inhibition of CD38+ MDSCs [128] -Reduction of CD38+ NK cells [128] -Increase in CD8+ T-cell cytotoxicity [128] Elotuzumab Anti-SLAMF7 ADCC ADCP [172] -Activation of NK cells [141] -Reduction of SLAMF7+ Treg cells [142] -Enhancement of DC activity [143,144]…”

Section: Monoclonal Antibodies (Mabs)mentioning

confidence: 99%

See 1 more Smart Citation

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?

Bertuglia

Cani

Larocca

et al. 2022

IJMS

View full text Add to dashboard Cite

Over the past two decades, the treatment landscape for multiple myeloma (MM) has progressed significantly, with the introduction of several new drug classes that have greatly improved patient outcomes. At present, it is well known how the bone marrow (BM) microenvironment (ME) exerts an immunosuppressive action leading to an exhaustion of the immune system cells and promoting the proliferation and sustenance of tumor plasma cells. Therefore, having drugs that can reconstitute a healthy BM ME can improve results in MM patients. Recent findings clearly demonstrated that achieving minimal residual disease (MRD) negativity and sustaining MRD negativity over time play a pivotal prognostic role. However, despite the achievement of MRD negativity, patients may still relapse. The understanding of immunologic changes in the BM ME during treatment, complemented by a deeper knowledge of plasma cell genomics and biology, will be critical to develop future therapies to sustain MRD negativity over time and possibly achieve an operational cure. In this review, we focus on the components of the BM ME and their role in MM, on the prognostic significance of MRD negativity and, finally, on the relative contribution of tumor plasma cell biology and BM ME to long-term disease control.

show abstract

Section: Influence Of Anti-mm Drugs On the Mementioning

confidence: 99%